17,261 trials
Schizophrenia
Primary: Change From Baseline to Week 24 in MATRICS Consensus Cognitive Battery (MCCB) Neurocognitive Composite Score — 32.50; 32.36; -0.17; -0.28 Composite T-Score — p=0.730
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Liver Transplant Recipient · Living Donor (of the Respective Liver Transplant Recipient)
Primary: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion — 0 Participants
Uveitis · Macular Edema · Uveitis, Posterior
Primary: Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following…
Chronic Sinusitis
Primary: Intra-operative Surgical Visibility - Boezaart Scale — 3.1; 3.1 score on a scale
Ebola Viral Disease
Primary: Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3) — 4; 6; 6; 62 Participants
Macular Edema · Retinal Vein Occlusion
Primary: Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm — 18; 7; 3; 12 Participants
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
Crohn's Disease
Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale
Diabetes Mellitus, Type 1
Primary: Safety and Tolerability as Measured by Adverse Events, Local Tolerability of Infusion Site Reactions, and Clinical Laboratory Parameters — 8; 12; 0; 0 Participants
Adenoid Hypertrophy
Primary: Average Pain Score — 0 pain score
HIV-1 Infection
Primary: Percentage of Participants With Successful Virological Suppression at Weeks 48 and 96 — 99.4; 98.7 percentage of participant
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities — 73; 62; 36; 16 Participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Period Baseline at Week 2 in Constant Work Rate (CWR) Endurance Time Relative to Placebo — -1.4; -13.4 seconds — p=0.734
Cocaine-related Disorder
Primary: Proportion of Cocaine Use Days — 0.122; 0.209 cocaine use days — p== 0.021